Skip to main content

Advertisement

Table 2 Median age of patients 48.5 (3–71)

From: Vaccination with dendritic cells loaded with allogeneic brain tumor cells for recurrent malignant brain tumors induces a CD4+IL17+ response

Patient ID Age Gender Performance status Diagnoses Number of vaccinations Time to progression (Weeks) Survival (Weeks) Maximum related toxicity/grade Response status
Patient 1 71 Male 80 GBM 2 4.2 34.6 ISR/1 Non-stable
Patient 2 61 Male 90 GBM 4 8 12.4   Non-stable
Patient 3 42 Female 80 GBM I Not evaluable N/A   Non-stable
Patient 4 55 Female 90 GBM 5 13.0 64.8 ISR/ 1 Stable
Patient 5 17 Male 70 GBM 10 30.6 53.3 lSR/1 Stable
Patient 6 63 Male 90 GBM 9 39.7 >92 ISR/1 Stable
Patient 7 3 Female 60 Epend 6 20.0 31.4 Fat/i  
ISR/3 Stable         
Patient 8 24 Female 90 Med 5 8.0 >92   Non-stable
Patient 9 53 Male 80 GBM 0 N/A N/A   Non-stable
Patient 10 13 Female 90 PNET 0 N/A N/A   Non-stable
Patient 11 49 Male 80 GBM 0 N/A N/A   Non-stable
Patient 12 48 Male 80 GBM 0 N/A N/A   Non-stable
  1. Male: Female 4:4. prior treatment regimes median (range) 1.5 (1–4). Performance Status (KPSansky), GBM Glioblastoma (WHO Grade IV), Epend = Ependymoma. Med = Medloblastoma, PNRT = primitive neuroectodemial tumor. ISR = Injection site skin reaction. Fat = Fatigue. Survival is measured in weeks post treatment Patients 9–12 failed trial prior to vaccination.